Medtronic Reaches 10 Million Implantable Devices Produced in Switzerland

In Switzerland, precision and innovation are more than values—they are an industrial signature. Few companies embody that better than Medtronic, which is celebrating a dual milestone: 50 years of presence in the country and the production of its 10 millionth implantable device at its Tolochenaz (Canton of Vaud) site.

A Swiss industrial success story

Medtronics first established operaiton in Canton of Vaud in 1976. Over five decades, the medtech company has built a deep-rooted ecosystem in Switzerland, combining high-precision manufacturing with engineering excellence and strong hospital partnerships. Today, the company employs more than 1,000 people nationwide and contributes significantly to the country’s life sciences sector—accounting for roughly 0.75% of total Swiss exports.

Its Tolochenaz facility, a global center of excellence, produces around 2,000 devices per day. That output translates into a striking global footprint: roughly one in four pacemakers and half of all implantable cardioverter defibrillators worldwide originate from Swiss production lines.

The milestone 10 millionth device was marked earlier this year with the implantation of a leadless pacemaker at Inselspital, Bern University Hospital, performed by renowned electrophysiologist Andreas Häberlin. The procedure highlights the close collaboration between Swiss clinical institutions and Medtronic’s innovation pipeline.

Innovation made in Switzerland

At the center of this achievement is Medtronic’s leadless pacemaker technology—one of the most advanced developments in cardiac care. Smaller, less invasive, and designed to reduce complications associated with traditional devices, it reflects a broader shift toward patient-centric, minimally invasive therapies.

The technology, first introduced in 2013 and continuously improved since, demonstrates how Swiss-based manufacturing and global R&D can translate into tangible clinical impact.

Investing in the next generation of innovation

Beyond manufacturing, Medtronic is also reinforcing its long-term commitment to Switzerland’s academic and innovation ecosystem. A few months ago, the company has announced support for a finance chair at École Polytechnique Fédérale de Lausanne (EPFL), with funding of CHF 4 million over eight years.

This investment signals a broader vision: strengthening the intersection of technology, healthcare, and economic strategy. By supporting academic research, Medtronic is helping to cultivate the expertise needed to navigate increasingly complex healthcare systems—where innovation must be matched with sustainable financial models.

➡️ Source: Press Release | 📸 ©Medtronic